Conditions: Atherosclerosis
Keywords: heart disease Lp-PLA2 inhibitor cardiovascular disease coronary heart disease CV risk Atherosclerosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15828
Healthy volunteers: no

Brief summary:
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.

Detailed description:
Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, and every 6 months until the end of the study. Average time in the study for an individual subject is expected to be about 3 years.

Arms:
arm 1: Single daily oral tablet arm 2: Single daily oral tablet

Interventions: intervention 1: Darapladib intervention 2: Placebo
Intervention descriptions: intervention 1: Lp-PLA2 inhibitor administered in addition to standard therapy intervention 2: Placebo administered in addition to standard therapy

Protocol document: